ImmuCell Reports Higher Quarterly and Year-to-Date Revenue, Operating Income, Net Income, and Diluted EPS Versus Prior Year

Bottom line

For both the three-month reporting period and the six-month year-to-date period covered by this filing, every profitability and top-line dimension tracked here moved in the same direction versus its prior-year comparative: higher. The following results are reported as positive in both the current and the prior-year window, so the change is best characterized as a profit-to-profit improvement on a higher base rather than a swing from loss to gain.

- Revenue from Contract with Customer, Excluding Assessed Tax was $7,186,113 USD for the three months ended June 30, 2026, higher than the $6,444,880 USD reported for the three months ended June 30, 2025. - Revenue from Contract with Customer, Excluding Assessed Tax was $17,543,408 USD for the six months ended June 30, 2026, higher than the $14,512,054 USD reported for the six months ended June 30, 2025. - Operating Income (Loss) was $1,934,934 USD for the three months ended June 30, 2026, higher than the $569,562 USD reported for the three months ended June 30, 2025. - Operating Income (Loss) was $3,904,250 USD for the six months ended June 30, 2026, higher than the $1,687,187 USD reported for the six months ended June 30, 2025. - Net Income (Loss) Attributable to Parent was $1,834,656 USD for the three months ended June 30, 2026, higher than the $501,880 USD reported for the three months ended June 30, 2025. - Net Income (Loss) Attributable to Parent was $3,776,263 USD for the six months ended June 30, 2026, higher than the $1,948,863 USD reported for the six months ended June 30, 2025. - Earnings Per Share, Diluted was $0.2 per diluted share USD/SHARES for the three months ended June 30, 2026, higher than the $0.06 per diluted share USD/SHARES reported for the three months ended June 30, 2025. - Earnings Per Share, Diluted was $0.41 per diluted share USD/SHARES for the six months ended June 30, 2026, higher than the $0.22 per diluted share USD/SHARES reported for the six months ended June 30, 2025.

The filing evidence does not attribute this change to any single cause.

Financial performance

- The interim filing for IMMUCELL CORP /DE/ (ICCC), filed as 10-Q for period-ended-2026-06-30 under accession 0001437749-26-027668, covers the three-month reporting period and the six-month year-to-date period, with the corresponding prior-year comparatives also disclosed.

Reported facts - Top line, bottom line, and operating result all moved higher on a year-over-year basis at both reporting windows. Revenue from Contract with Customer, Excluding Assessed Tax for the six months ended June 30, 2026 was higher than the six months ended June 30, 2025 $17,543,408 vs $14,512,054, and for the three months ended June 30, 2026 it was higher than the three months ended June 30, 2025 $7,186,113 vs $6,444,880. - Net Income (Loss) Attributable to Parent for the six months ended June 30, 2026 was higher than the six months ended June 30, 2025 $3,776,263 vs $1,948,863, and for the three months ended June 30, 2026 it was higher than the three months ended June 30, 2025 $1,834,656 vs $501,880. In each case the transition was profit to profit. - Operating Income (Loss) for the six months ended June 30, 2026 was higher than the six months ended June 30, 2025 $3,904,250 vs $1,687,187, and for the three months ended June 30, 2026 it was higher than the three months ended June 30, 2025 $1,934,934 vs $569,562. Again, the transition was profit to profit. - Earnings Per Share, Diluted for the six months ended June 30, 2026 was higher than the six months ended June 30, 2025 $0.41 per diluted share vs $0.22 per diluted share, and for the three months ended June 30, 2026 it was higher than the three months ended June 30, 2025 $0.2 per diluted share vs $0.06 per diluted share, with the transition profit to profit.

Management explanations - Management ties the period to a December decision to cease Re-Tain development and to repurpose the related equipment for First Defense production, with the change in useful-life estimate discussed in Note 5 and the strategic shift explained further under Item 1. - Management highlights seasonality, noting First Defense sales typically run higher during the first quarter of the calendar year because of the beef calving season from January to April, and flags weather-driven variability in producer demand, as discussed under Item 1. - Management cites the First Defense manufacturing expansion program, with the initial phase renovating the former Re-Tain facility and adding a higher-capacity freeze dryer and a second phase expanding colostrum liquid processing, as described under Item 1A and Item 7. - Management cites higher product volumes across First Defense categories, including portfolio expansion and price increases, alongside a shift of certain costs from product development expense to costs of goods sold as the former Re-Tain facility was repurposed for First Defense production. - Management also calls out higher executive compensation and professional services fees, expanded First Defense commercial efforts, the Caddie facility cost shift referenced in Note 5, and a settlement with a former contract manufacturer recorded in other operating income.

Analyst inference - Because every authorized direction for revenue, operating income, net income, and diluted EPS is "increase" and the period type is profit to profit in each comparison, the analyst inference is that the reported financial performance was stronger on a year-over-year basis across both the quarter and the six-month year-to-date windows. Comparing the two periods, the underlying revenue, net income, and operating result continue to read as higher than the prior year, with no authorized direction that implies a reversal. Readers evaluating the return profile generated by these interim results can cross-check with ROI Calculator before acting.

Counter-evidence and unknowns - The filing evidence does not include peer or industry data, so a relative-scale read against other animal-health issuers is not available here. - The filing evidence does not disclose segment-level detail beyond the product-line color management provides, so a true segment breakdown is not available for this filing. - The filing evidence does not attribute the year-over-year change in revenue, operating income, net income, or diluted EPS to any single cause. The filing evidence does not attribute this change to any single cause.

Operating drivers and segments

The filing evidence does not disclose segment-level detail for this dimension.

The filing describes IMMUCELL CORP /DE/ as a single animal-health biologics business centered on the First Defense® product line, with smaller contributions from CMT and the now-paused Re-Tain® program. Management characterizes the quarter as benefiting from "higher sales volumes for all product categories of the First Defense® product line, including portfolio expansion, and product price increases," and frames the year-over-year improvement in operating results as reflecting that volume-plus-price combination across both reporting windows.

Management also flags two structural items that touched reported results. First, a settlement with a former contract manufacturer compensated the Company for "operating costs incurred in product development and contract performance related to the development of the Company's Re-Tain® product," so a portion of the period's reported figures is tied to that one-time recovery rather than to recurring commercial activity. Second, a separate "income from insurance recoveries resulted from claim benefits paid to us during the first quarter" of the current year under a business interruption policy tied to "product contamination losses incurred during late" the prior period and into early this year; this is presented as another non-recurring item layered on top of the underlying business. Management further notes that international sales were a material share of total product sales during both the three-month and six-month windows, and that CMT contributed only a single-digit slice of product sales across the periods reported.

On capacity, management disclosed a multi-phase First Defense® Manufacturing Expansion that converts former Re-Tain® facilities into drying and liquid-processing capacity for First Defense®, with the initial phase expected to last roughly the cited number of months and cost in the cited low-tens-of-millions range, and a second phase expected to add another half-year of work at a similar incremental cost. Management emphasizes that the goal is "to further strengthen our ability to reliably manufacture First Defense® products to meet expected customer demand." A separate accounting estimate change extended the useful lives of certain previously idle Re-Tain® equipment by a weighted average of five years, which the Company discloses under the change-in-accounting-estimate discussion cross-referenced in the cited property, plant and equipment note.

Operating drivers read through this lens are dominated by First Defense® volume and price on the top line, partially offset by capacity-related operating costs and partially cushioned by the contract-manufacturer settlement and the business-interruption insurance recovery. Independent analysis cannot decompose the operating result further from the filing evidence: there is no disclosed segment split beyond the product-level color above, so margin attribution between product lines, geography, and the one-time items cannot be reconstructed. Revenue moved higher year over year in both the three-month and six-month windows reported in this filing, and operating income also moved higher in both windows, but The filing evidence does not attribute this change to any single cause.

No peer or industry benchmark is provided in the filing, so The filing evidence contains no peer or industry comparison. Readers weighing the capacity-expansion spend disclosed in the cited phase descriptions can stress-test the trade-off with a tool such as ROI Calculator.

Cash flow and capital

- Operating cash generation strengthened year over year for the six-month year-to-date period, with Net Cash Provided by (Used in) Operating Activities rising on the authorized increase relative to the prior-year comparative. - Within that operating result, working-capital movements featured a smaller cash outflow for inventory tied to finished-goods build-up earlier in the cycle, a smaller cash use for accounts payable and accrued expenses that the filing ties to the timing of payroll and executive bonus payments, and a smaller cash inflow from accounts receivable reflecting the timing of order fulfillment.

- The current six-month period also absorbed higher share-based and executive compensation and added legal and professional service fees, with the latter item also called out as a discrete driver in management's narrative. - Investing activities were a net use of cash in both six-month windows, and the current period's outflow was larger than the prior-year comparative on the authorized decrease, reflecting heavier Payments to Acquire Property, Plant, and Equipment. - Management attributes the higher capex principally to spending supporting the first phase of the First Defense planned production increase, with property, plant and equipment disclosures elaborated in the cited property, plant and equipment note.

- Financing activities were a net use of cash in both six-month windows, and the current period's outflow exceeded the prior-year comparative on the authorized decrease, consistent with recurring debt principal repayments on the existing facility (excluding the bank line of credit) and with debt service noted in the liquidity discussion. - Liquidity sources cited by management are operating cash flow, common stock issuance proceeds, and the available bank line of credit, which carries a National Prime Rate per annum pricing structure and remains available through a September renewal date.

- Management indicates it anticipates some level of tax liability moving forward as certain net operating losses carried forward no longer offset taxable income in the same proportion, with the residual portion instead offsetting future taxable income — a disclosure tied to the deferred tax position and to the related tax footnote discussion. - On the balance sheet, Cash and Cash Equivalents stood at a positive carrying value at the balance sheet date of the instant, while Long-term Debt, Excluding Current Maturities was also positive at that date, leaving the company carrying a long-dated borrowing position alongside its cash buffer.

- Short-term obligations were anchored by Accounts Payable and Accrued Liabilities, Current and by Accounts Payable, Interest-bearing, Current, both reported as positive balances at the balance sheet date, indicating that trade and interest-bearing payables together form the principal near-term funding footprint. - Management flags a settlement with a former contract manufacturer as Other Operating Income for the six months, reflecting compensation for operating costs the Company incurred developing the Re-Tain product — a discrete item disclosed in the cited operating-expense discussion and one that lifts reported other operating income versus the prior-year comparative.

- Capital-allocation emphasis remains on the First Defense production build-out, with management describing refit work at the Caddie facility following the December decision to cease efforts to obtain FDA approval of Re-Tain and to repurpose the site for First Defense production. - The shift reclassifies depreciation and building-related expenses from product development expense into costs of goods sold, which the filing ties to the cost-of-goods-sold movement discussed in the operating-results narrative and to the property, plant and equipment footnote.

- Recurring debt principal repayments (excluding the line of credit) were disclosed at roughly comparable levels in both six-month windows, and management projects a similar run-rate of recurring repayments for the full year ending December, framing capital allocation as a continuation of measured deleveraging rather than balance-sheet expansion. - The operating lease footnote context included in the cited notes indicates that lease-related right-of-use assets, net are reported alongside property, plant and equipment, an item that supports the broader non-debt financing footprint but is not separately quantified in this section.

- The internal-control and Sarbanes-Oxley-related disclosure referenced in the cited Section language applies to the certification architecture rather than to the cash-flow or capital-allocation mechanics discussed above. - The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison.

Peer and historical context

- The filing evidence contains no peer or industry comparison, so the only relative lens available is the company's own year-over-year history. The filing evidence contains no peer or industry comparison. - Across every line item the catalog carries — revenue, operating income, net income and operating cash flow — the authorized year-over-year direction is higher in the current period than the same window a year earlier, in both the three-month reporting period and the six-month year-to-date period. Operating cash flow specifically is authorized as higher for the half-year window, reinforcing that the improvement is broad-based rather than confined to the top line.

- The improvement in operating income and net income sits on a backdrop where the filing's own narrative flags that other (expenses) income, net moved to an expense for the six-month year-to-date window relative to the prior-year comparative, which is a mild offset to the operating-line strength. - The filing also discloses tighter product supply that constrained commercial spending for part of the first half, with relief arriving later in the summer. That supply-driven curb on selling activity is a separate offset worth weighing against the headline revenue growth. - Capital expenditure cash outflows related to the first phase of the planned First Defense production increase rose versus the prior-year comparative, and financing-activities outflow widened primarily because the prior-year comparative included ATM Agreement proceeds not repeated this period. Both flows can pressure reported earnings quality even while headline earnings expand.

The historical comparison therefore reads as uniformly constructive on the authorized dimensions: revenue, operating income, net income and operating cash flow are each authorized as higher in the current reporting windows than the prior-year comparables, with operating income and net income remaining profitable across all four windows. The picture softens once the non-operating line, the supply-curb effect on commercial spending, and the heavier investing- and financing-activities cash use are layered in. Management also signals that certain NOL carryforwards no longer offset taxable income in the same way, which is a forward-looking consideration for after-tax comparability but does not by itself undermine the reported improvement. The filing evidence does not attribute this change to any single cause.

Readers checking how this kind of revenue-and-earnings lift translates into shareholder returns can pair the discussion with ROI Calculator when they model their own assumptions.

Scenario analysis

- Reported reality for IMMUCELL CORP /DE/ (ICCC) under 10-Q for the three months ended June 30, 2026 and the six months ended June 30, 2026, against the prior-year comparatives the three months ended June 30, 2025 and the six months ended June 30, 2025, is the central anchor. Revenue from Contract with Customer, Excluding Assessed Tax was $7,186,113 USD for the three months ended June 30, 2026 versus $6,444,880 USD for the three months ended June 30, 2025, and $17,543,408 USD for the six months ended June 30, 2026 versus $14,512,054 USD for the six months ended June 30, 2025. Net Income (Loss) Attributable to Parent was $1,834,656 USD for the three months ended June 30, 2026 versus $501,880 USD for the three months ended June 30, 2025, and $3,776,263 USD for the six months ended June 30, 2026 versus $1,948,863 USD for the six months ended June 30, 2025.

- The upside requires management to translate the higher reported top line and reported bottom line into capacity that captures the demand-side opportunity disclosed in Item 1A. The excerpt describes planned incremental freeze drying capacity and colostrum processing capacity over the coming months; absent operational friction on yields, contamination or raw-material supply, that spending profile could convert the order backlog into sustained revenue growth and improve the reported profit margin. Stronger cash generation could also relieve the reported net cash used in financing and investing lines flagged in Item 7 commentary. Readers can sense-check the math of converting incremental capacity into return on invested capital with ROI Calculator.

- The downside is operational. Item 1A highlights production capacity constraints, colostrum supply concentration in essentially one state, and the practical risk that farms exit the collection network or that disease impairs supply. If any of those crystallizes, the reported revenue base could stall even while the higher reported earnings of the current periods set the comparison bar, eroding the authorized direction increase on the top line. Contingency exposure is flagged in Note 9, and management has not committed to a specific offsetting plan beyond incremental investment, leaving The filing evidence does not attribute this change to any single cause. for any single-driver story behind margin movement. The legal-proceedings note in Item 1A does not identify a pending matter that would itself bend the base case, but a sudden adverse outcome would layer onto the operational risks already disclosed.

Risks and what to watch

- Reported facts: The filing from IMMUCELL CORP /DE/ under accession 0001437749-26-027668 for the period-ended-2026-06-30 period on 10-Q provides the headline reported figures without their counter-causes. Net Income (Loss) Attributable to Parent came in at $1,834,656 USD for the three-month window the three months ended June 30, 2026 and at $3,776,263 USD for the six-month window the six months ended June 30, 2026. Revenue from Contract with Customer, Excluding Assessed Tax landed at $7,186,113 USD for the three months ended June 30, 2026 and at $17,543,408 USD for the six months ended June 30, 2026.

The prior-year comparatives show $501,880 USD for the three months ended June 30, 2025, $1,948,863 USD for the six months ended June 30, 2025, $6,444,880 USD for the three months ended June 30, 2025, and $14,512,054 USD for the six months ended June 30, 2025. - Management explanations and risk call-outs: Management discloses, in Item 1 discussing seasonality and Item 1A covering risk factors, several structural exposures. Production capacity constraints are highlighted, noting planned incremental freeze-drying investment and colostrum processing investment over the next several months.

Colostrum collection is flagged as geographically concentrated (almost entirely in one state) with disease-outbreak, farm-participation, and raw-quality risks. Legal proceedings, addressed under Part II Item in this filing, are described as ordinary-course and not currently expected to have a material adverse effect, per management. Accounting detail behind the carrying values sits in Note 5 (property, plant and equipment) and Note 9 (referenced discussion).

MD&A context sits in Item 7, and Section Section 13 references the Sarbanes-Oxley certifications. - Analyst inference: The filing evidence does not disclose segment-level performance or product-line splits, so any read on which SKU is carrying growth versus back-pressure cannot be made from this filing alone. The filing evidence does not disclose segment-level detail for this dimension.

- Counter-evidence to the bull reading: Year-over-year, revenue is authorized as an increase in both windows but earnings-related dimensions (net income, operating income, diluted EPS) are authorized as increases in both windows — meaning the topline and bottom-line stories move in the same authorized direction; no divergence is disclosed. Investing and financing cash flows are authorized as decreases (more negative) versus the prior year, while operating cash flow is authorized as an increase — useful cross-checks but not a counter-signal in themselves.

- Unknowns: Cause for the higher revenue and earnings versus prior year is not stated in the evidence; The filing evidence does not attribute this change to any single cause.. Backlog level, realized price per dose, and any unit-volume versus price-mix split are not in the catalog. The filing evidence contains no peer or industry comparison.

Peer or industry benchmarks are absent. - Metrics to watch next period: Re-Tain® launch traction, First Defense® order backlog conversion, freeze-drying and colostrum processing commissioning milestones, supplier-farm retention and disease status in the concentrated sourcing region, and operating cash flow versus the higher capex outflows disclosed via investing activities.